Voiding Dysfunction

A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

Other female urology topics discussed at this year's AUA meeting include preoperative urodynamics for women undergoing prolapse surgery and a study on nocturia.

Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.

Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.

Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.

In this video, Neil Baum, MD, compares UroLift with other BPH management strategies and also discusses his experience with the use of nitrous oxide as an effective sedative during in-office urologic procedures.

This video demonstrates UroLift placement under topical anesthesia in the office setting and also includes comments from several patients who underwent the procedure.

This video provides an overview of the prostatic urethral lift (UroLift), highlighting the entire cycle of patient care.

Although there is no clear-cut solution to the problem of recurrent UTIs in postmenopausal women, "various strategies can be employed that have found success," write Wade Bushman, MD, PhD, and Brian V. Le, MD, MA.

An image-guided technique for treating LUTS associated with BPH is reproducible and promising, researchers say.

A new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter.

Preliminary findings of a Swiss study revealed that the brain activity associated with the desire to void in response to the automated, repetitive filling and distention of the bladder with body warm saline differed greatly between healthy patients and patients with non-neurogenic overactive bladder.

Gynecologists derive higher complication rates than urologists during the first 30 days following sling procedures for urinary incontinence, according to a multicenter study presented at the European Association of Urology annual congress in Munich, Germany.

"An abstract authored by Löppenberg et al is an interesting analysis of information from a respected prospective database examining variations in the quality of care provided to patients undergoing sling placement by gynecologists and urologists," write Seth A. Cohen, MD, and Shlomo Raz, MD.

To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.

A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.

Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.

An increasing proportion of certifying and recertifying urologists are women, and they perform a disproportionate volume of female urology cases, researchers at Northwestern University in Chicago found.

Lower urinary tract symptoms (LUTS) are not just a problem with staying asleep. Difficulty with sleep may actually impact LUTS, say researchers at Baylor College of Medicine in Houston.

Overactive bladder (OAB) and falls often carry a substantial burden for patients and society as a whole, and new research suggests that treatment of OAB may lower fall risk. Learn more

Check out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.

Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.

Learn more about these products as well as a powered exam table and an app that measures, monitors, and helps improve fertility in men.

Economic analyses of surgeries to treat SUI also do not routinely capture long-term complications, researchers say.

Study examines real-world effectiveness of percutaneous tibial nerve stimulation for treating overactive bladder.

In this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

The authors evaluated cumulative incidence of re-operation after various surgical procedures for urinary incontinence within 5 years.

A recent systematic review found that the total incidence of serious complications and/or sling failure with respect to incontinence was 15.3%.